rs10928874 - ISCA1P6 - LINC01854
Magnitude 2.2 · 1 study on file
Reported associations
-
A Genome-Wide Association Study of Nausea Incidence in Varenicline-Treated Cigarette Smokers. - Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2021) · Chenoweth MJ, Lerman C, Knight J, Tyndale RF · PubMed 33713409
Varenicline is the most efficacious smoking cessation treatment; however, long-term cessation rates tend to be <25%. Nausea, the most common side effect of varenicline, observed in ~28% of individuals treated, peaks early following treatment initiation and reduces cessation success. Genetic variation influences treatment response, however genetic contributors to individual differences in side effects are less understood. We conducted a genome-wide association study of nausea incidence at 1 week following the initiation of varenicline treatment (corresponding to the target quit date) in 189 cigarette smokers of European ancestry (NCT01314001). Additive genetic models examining the likelihood of experiencing any versus no nausea controlled for population substructure, age, and sex. Variants
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
varenicline nausea risk before smoking cessation Moderate
This SNP associates with increased nausea when using varenicline for smoking cessation, suggesting pharmacogenetic sensitivity.
Discuss with prescriber before starting varenicline; consider alternative cessation methods if nausea risk concerns you.